SCHEMBL4408961

SCHEMBL4408961

CC(C)(C)OC(=O)N1CCN2C(=O)c3c(Br)cccc3OCC2C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.43
MEN1 O00255 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39
GABRA2 P47869 1/20 0.39
KMT2A Q03164 1/20 0.39
GABRA6 Q16445 1/20 0.39
TP53 P04637 1/20 0.39
FPR2 P25090 2/20 0.38
SETD7 Q8WTS6 1/20 0.37
SCN9A Q15858 1/20 0.37
HDAC6 Q9UBN7 2/20 0.37
UCHL1 P09936 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
ABCB1 P08183 1/20 0.37
PRMT5 O14744 2/20 0.35
WDR77 Q9BQA1 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4412319 0.88 USP30 (0.43) USP30MEN1KMT2ATP53SCN9A
SCHEMBL4410012 0.87 USP30 (0.42) USP30TP53SCN9A
SCHEMBL4411273 0.86 USP30 (0.44) USP30TP53FPR2SCN9A
SCHEMBL4415998 0.86 USP30 (0.42) USP30TP53SCN9AHDAC6HDAC8
SCHEMBL4411286 0.85 USP30 (0.44) USP30HDAC6UCHL1HDAC8ABCB1
SCHEMBL4410015 0.85 SCN9A (0.42) USP30TP53SCN9AHDAC6HDAC8
SCHEMBL4410161 0.84 USP30 (0.43) USP30TP53FPR2SETD7SCN9A
SCHEMBL4408213 0.83 USP30 (0.43) USP30TP53SCN9AHDAC6HDAC8
SCHEMBL4418327 0.83 USP30 (0.40) USP30MEN1KMT2ATP53SETD7
SCHEMBL4410458 0.82 USP30 (0.39) USP30TP53FPR2SCN9AHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318412-A1 Tricyclic heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318412-A1 Tricyclic heterocyclic compound and use thereof HTR2C, HTR2A, HTR5A USP30 4369/4885MEN1 1646/4885GABRA1 663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.